F06.7
Conditions
Interventions
Group 1: Group 1 (passive): A group of 99 participants with mild cognitive impairment will be asked to maintain their previous level of physical activity for three year.
Group 2: Group 2 (active):
A g
Sponsors
The National Science Centre
Eligibility
Sex/Gender
All
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: • Age: 50 – 70 years; • Diagnosed diminished or mild cognition impairment (result of the MoCA tests: 19-26 points); • Living in a community dwelling; • Owning a smartphone
Exclusion criteria
Exclusion criteria: • Treated depression and/or the results of the Hamilton depression test > 13 points; • The use of cognitive boosting medications or psychotropic medications; • Substance abuse disorders (e.g. alcohol - >15 drinks (units)/week); • Diagnosed psychiatric disorders, Parkinson’s disease Alzheimer’s disease, dementia; • Anaemia; • Diabetes for >10 year; • Chronic renal and liver diseases; • History of serious cancer treated with chemotherapy or radiation therapy within the past 5 years; • History of stroke; • Current evidence or history in the past 2 years of seizures, head injury with loss of consciousness and/or immediate confusion after the injury; • Hypothyroidism with current misaligned TSH levels; • Any chronic diseases that might have limited training and testing of the cardiovascular and respiratory systems; • Current vigorous physical activity for more than 150 min/week of moderate physical activity or 75 min/week of vigorous physical activity or an equivalent combination of moderate to vigorous physical activity and/or 10,000 steps/day; • Pacemaker, neurostimulator, implanted metal components, including prosthetic implant; • Claustrophobia • Blindness, deafness, language difficulties or any other disability which may prevent the subjects from participating or cooperating in the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the cognitive function assessed by a neuropsychological test battery and the Montreal Cognitive Assessment scale (MoCA) evaluated before and after one and three years of the intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the following parameters: • markers of neuronal growth/destruction (BNDF, plasma amyloid ß-40: ß-42 ratio and Tau protein); • brain magnetic resonance imaging (brain volume, presence of ischaemic incidents); • inflammatory markers (IL-6, IL-1R-a, TNF-a, hsCRP); • anthropometric parameters (body weight, waist and hip circumferences, body mass index (BMI)); • body composition (fat-free mass (FFM), fat mass (FM)); • densitometric parameters (bone mineral content (BMC) and bone mineral density (BMD)); • blood pressure; • dietary habits. Biochemical parameters and magnetic resonance will be measured before and after one and three years of the intervention. Anthropometric parameters, body composition, densitometric parameters, blood pressure and dietary habits will be assessed before, during and after the intervention period. | — |
Countries
Poland
Contacts
Public ContactJaroslaw Walkowiak
Department of Pediatric Gastroenterology and Metabolic DiseasesPoznan University of Medical Sciences
Outcome results
None listed